Bank of Nova Scotia Gets Fed Approval for Acquisition of 15% Stake in KeyCorp-June 2024-www.financetom.com

Bank of Nova Scotia Gets Fed Approval for Acquisition of 15% Stake in KeyCorp

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Bank of Nova Scotia Gets Fed Approval for Acquisition of 15% Stake in KeyCorp

Dec 13, 2024 3:41 AM

06:10 AM EST, 12/13/2024 (MT Newswires) -- Bank of Nova Scotia ( BNS ) has received the US Federal Reserve's approval to increase its interest in KeyCorp ( KEY ) to up to 14.99% from 4.93%, the Fed said Thursday.

The Canadian bank announced its bid to acquire up to about 15% stake in KeyCorp ( KEY ) in August for a total cash consideration of about $2.8 billion.

Previous page： Axsome Therapeutics Says It Settled Sunosi Patent Litigation With Unichem Laboratories Next page： Mind Medicine Shares Fall After FDA Committee Votes Against Lykos Therapeutics' Psychedelic Drug

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Axsome Therapeutics Says It Settled Sunosi Patent Litigation With Unichem Laboratories

Jun 5, 2024

08:27 AM EDT, 06/05/2024 (MT Newswires) -- Axsome Therapeutics ( AXSM ) said Wednesday it has settled patent litigation with Unichem Laboratories regarding Axsome's sleep disorder drug Sunosi. The pharmaceutical company said the litigation, pending in the United States District Court for the District of New Jersey, arose after Unichem applied for the US Food and Drug Administration's approval to...

Mind Medicine Shares Fall After FDA Committee Votes Against Lykos Therapeutics' Psychedelic Drug

Jun 5, 2024

08:25 AM EDT, 06/05/2024 (MT Newswires) -- Mind Medicine's (MNMD) shares were down 9% in Wednesday's premarket activity, a day after advisers to the US Food and Drug Administration voted against Lykos Therapeutics' psychedelic drug. Lykos Therapeutics said late Tuesday that advisers to the US Food and Drug Administration have voted against its therapy based on the mind-altering drug midomafetamine,...

Montrose Environmental Acquires Canada-based Paragon Soil & Environmental Consulting

Jun 5, 2024

08:25 AM EDT, 06/05/2024 (MT Newswires) -- Montrose Environmental Group ( MEG ) said Wednesday that it has acquired Paragon Soil & Environmental Consulting, a Canada-based environmental consulting firm. Financial terms of the deal were not disclosed. Price: 43.54, Change: -0.43, Percent Change: -0.98 ...

Calibre Reports Additional Gold Mineralization at Valentine Gold Mine Complex in Newfoundland & Labrador

Jun 5, 2024

08:26 AM EDT, 06/05/2024 (MT Newswires) -- Calibre (CXB.TO), which lost 4% yesterday, on Wednesday highlighted drill results from its 2024 exploration program within its 250-square-kilometer Valentine Gold Mine complex in Newfoundland & Labrador, Canada. Among the highlights, the company reported 2.25 g/t of gold over 15.30 meters estimated true width, including 24.68 g/t of gold over 0.85 meters estimated...